This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Orexigen, Takeda Tie Knot on Obesity Drug

SAN DIEGO ( TheStreet) -- The going rate the Japanese are willing to pay for development rights to a unapproved obesity drugs seems to be $50 million.

A $50 million upfront fee is what Takeda Pharmaceutical Co. will pay Orexigen Therapeutics (OREX) to secure North American marketing rights to Contrave, Orexigen's experimental obesity drug, according to terms announced Thursday.

This partnership follows a similar deal announced in July in which Japanese drug maker Eisai also paid $50 million upfront for U.S rights to Arena Pharmaceuticals' (ARNA) obesity drug lorcaserin.

Orexigen shares closed Wednesday at $4.59, ahead of the partnership announcement.

The relatively small upfront payments, especially for drugs already under review by the U.S. Food and Drug Administration, reflect a cautious outlook towards the approvability and commercial potential for these drugs. It's also worth noting that to date, none of the large U.S.-based pharmaceutical companies have been willing to sign obesity drug deals.

The Orexigen-Takeda partnertship leaves Vivus (VVUS) as the only U.S.-based obesity drug developer without a larger marketing partner. An FDA advisory panel in July voted against recommending approval of Vivus' Qnexa, fearing the drug's long-term safety.

Similar FDA panels will be reviewing Arena's lorcaserin on Sept. 16 and Orexigen's Contrave on Dec. 7.

In exchange for the $50 million upfront payment, Takeda receives exclusive Contrave marketing rights to Contrave in the U.S., Canada and Mexico. Orexigen will have the right to co-promote the drug. Takeda will pay upwards of an additional $1 billion to Orexigen upon Contrave achieving certain, undisclosed, regulatory and sales-based milestones. Takeda will also pay tiered double-digit royalty payments on net sales of Contrave in North America.

Again, the future terms of the Orexigen-Takeda partnership mirror those signed earlier by Arena and Eisai.

Contrave is similar to Vivus' Qnexa in that it's a two-drug combination designed to help patients lose weight. Contrave consists of two currently approved drugs combined together to suppress appetite and fight food cravings. One of the drugs in Contrave is naltrexone, currently used to fight opioid and alcohol addiction; the other drug is the antidepressant bupropion.

Phase III studies demonstrated that Contrave helps patients lose weight, but the drug also causes an increase in blood pressure, which has raised some doubts about the drug's approvability, especially in an regulatory environment where the cardiovascular safety of weight-loss drugs is being heavily scrutinized.

On Sept. 15, an FDA panel will consider whether to allow Abbott Labs to continue selling the weight-loss drug Meridia after a long-term study tied the drug's use to an increase in heart attacks and strokes. Meridia also causes an increase in blood pressure and heart rate.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%
YHOO $27.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs